In addition to being highly effective in preventing Covid illness of any severity, the vaccine was 100 per cent effective in preventing moderate and severe disease that required hospitalisation, revealed the study published in the New England Journal of Medicine.
The recombinant nanoparticle protein-based Covid-19 vaccine showed 90.4 percent efficacy in the clinical trials in the US
Under the terms of its agreement with the Department of Health and Human Services (HHS) and Department of Defense, Novavax agrees to deliver 100 million doses of its vaccine, potentially by the end of the year.
